| Title |
β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?
|
|---|---|
| Published in |
Current Urology Reports, May 2013
|
| DOI | 10.1007/s11934-013-0335-8 |
| Pubmed ID | |
| Authors |
Karl-Erik Andersson |
| Abstract |
The new information generated over the last decade on the physiology/pharmacology of the normal bladder and on the pathophysiology of the overactive bladder has resulted in the introduction of a new therapeutic principle, β3-adrenoceptor (AR) agonism, and the approval of mirabegron, a selective agonist at β3-ARs. It may be asked in what respects the β3-AR agonists as a group, and mirabegron in particular, differ from the antimuscarinics, and what can clinically be gained by the β3-AR agonists. In this short review, the mechanisms of action, clinical efficacy, and adverse effect profiles of the two groups of drugs are compared and discussed. |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 28% |
| Student > Master | 3 | 10% |
| Student > Doctoral Student | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Other | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 9 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 38% |
| Nursing and Health Professions | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Engineering | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 14 | 48% |